A extracellular secretion of miR-1825 wrapped by exosomes increases CLEC5A expression: a potential oncogenic mechanism in ovarian cancer

Author:

Wu Qiaoling1,Cui Zhaolei1,Xia Hongmei1,Jiang Shan1,Bai Jing2,Shao Zhuo2,Sun Yang1

Affiliation:

1. Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital

2. Geneplus-Beijing Institute

Abstract

Abstract Background: Ovarian cancer (OC) is an important cause of gynecologic cancer-related mortality worldwide. Exosomal miR-1825 and its target gene CLEC5A have been shown to have a significant association with tumorigenesis in other cancers. Methods: Exosomal miR-1825 expression and its ability in overall survival(OS) prediction were determined using GEO and TCGA data. Target genes of miR-1825 were searched in five prediction databases, and differentially expressed prognostic genes were identified. We performed GO and KEGG enrichment analyses. The ability of CLEC5A in OS prediction was assessed using univariate and multivariate Cox regression and Kaplan-Meier curves. Immunohistochemistry was applied to validate the CLEC5A expression pattern in OC. The immune cell landscape was compared using the CIBERSORT algorithm, and the results were validated in a GEO cohort. Finally, the predicted IC50 of five common chemotherapy agents was compared. Results: MiR-1825 was elevated in exosomes derived from OC cells and served as a tumor suppressor. The CLEC5A gene was confirmed as a target of miR-1825, whose upregulation was correlated with a poor prognosis. M2 macrophage infiltration was significantly enhanced in CLEC5A high expression group, and T follicular helper cell infiltration was reduced in it. The predicted IC50 for cisplatin and doxorubicin was higher in CLEC5A high expression group, and that for docetaxel, gemcitabine, and paclitaxel was lower. Conclusion: MiR-1825 may promote OC progression by increasing CLEC5A expression through exosome-mediated efflux from tumor cells and could be a promising biomarker for OC.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3